Table 4.
Serological Response to Treatment of Venereal Disease Research Laboratory and Pathozyme Immunoglobulin M According to Clinical Stage of Syphilis and HIV Statusa
| Baseline | Primary Syphilis | Secondary Syphilis | Latent Syphilis | HIV Uninfected | HIV Infected |
|---|---|---|---|---|---|
| VDRL | (n = 52) | (n = 133) | (n = 29) | (n = 117) | (n = 97) |
| At 90 days | 92 (85–100) | 83 (76–89) | 62 (44–79) | 86 (80–92) | 77 (68–85) |
| At 180 days | 100 | 99 (97–100) | 76 (60–91) | 96 (93–99) | 94 (90–99) |
| At 270 days | 100 | 100 | 83 (69–97) | 98 (96–100) | 97 (95–100) |
| At 360 days | 100 | 100 | 93 (84–102) | 98 (96–100) | 100 |
| At 540 days | 100 | 100 | 93 (84–102) | 98 (96–100) | 100 |
| Pathozyme-IgM | n = 86 | n = 121 | n = 26 | n = 138 | n = 95 |
| At 90 days | 35 (24–45) | 22 (14–29) | 31 (13–49) | 26 (19–33) | 30 (21–39) |
| At 180 days | 66 (55–76) | 44 (35–54) | 46 (27–66) | 52 (43–61) | 54 (43–64) |
| At 270 days | 81 (72–90) | 54 (45–64) | 68 (48–87) | 62 (53–71) | 70 (60–80) |
| At 360 days | 87 (79–95) | 62 (52–72) | 74 (54–94) | 73 (64–81) | 75 (66–85) |
| At 540 days | 94 (87–101) | 79 (69–90) | 74 (54–94) | 85 (75–95) | 86 (77–95) |
| At 720 days | 100 | 100 | 74 (54–94) | 92 (82–103) | 100 |
Patients with tertiary syphilis were excluded.
Abbreviations: HIV, human immunodeficiency virus; IgM, immunoglobulin M; VDRL, Venereal Disease Research Laboratory test.
a Data are estimated percentage of cases (estimated 95% confidence interval) based on Kaplan-Meier analysis.